MDT

84.21

-0.14%↓

VEEV

226.67

-0.19%↓

A

106.17

-0.03%↓

WBA

11

-0.09%↓

CHE

555.99

+0.34%↑

MDT

84.21

-0.14%↓

VEEV

226.67

-0.19%↓

A

106.17

-0.03%↓

WBA

11

-0.09%↓

CHE

555.99

+0.34%↑

MDT

84.21

-0.14%↓

VEEV

226.67

-0.19%↓

A

106.17

-0.03%↓

WBA

11

-0.09%↓

CHE

555.99

+0.34%↑

MDT

84.21

-0.14%↓

VEEV

226.67

-0.19%↓

A

106.17

-0.03%↓

WBA

11

-0.09%↓

CHE

555.99

+0.34%↑

MDT

84.21

-0.14%↓

VEEV

226.67

-0.19%↓

A

106.17

-0.03%↓

WBA

11

-0.09%↓

CHE

555.99

+0.34%↑

Search

Merck & Co Inc.

Deschisă

SectorSănătate

83.14 5.01

Rezumat

Modificarea prețului

24h

Curent

Minim

78.07

Maxim

83.08

Indicatori cheie

By Trading Economics

Venit

583M

3.7B

Vânzări

-1B

16B

P/E

Medie Sector

11.55

57.333

EPS

1.72

Randament dividend

4.15

Marjă de profit

23.963

Angajați

73,000

EBITDA

1.3B

6.9B

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+35.27% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

4.15%

2.63%

Data viitoare de dividende

7 iul. 2025

Următoarea dată ex-dividende

16 iun. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-56B

196B

Deschiderea anterioară

78.13

Închiderea anterioară

83.14

Scor tehnic

By Trading Central

Încredere

Bullish Evidence

Merck & Co Inc. Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

9 apr. 2025, 18:18 UTC

Principalele dinamici ale pieței

Pharma Shares Reverse Losses After Tariff Pause

9 apr. 2025, 09:39 UTC

Principalele dinamici ale pieței

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

4 feb. 2025, 12:33 UTC

Câștiguri

Merck 4Q Earnings Rise; 2025 Outlook Hits Shares -- Update

4 feb. 2025, 11:57 UTC

Câștiguri

Merck 4Q Sales Increase Results in Swing to Profit

24 apr. 2025, 20:08 UTC

Câștiguri

Gilead Sciences Earnings Were Solid. How the S&P 500's No. 1 Health Stock Did. -- Barrons.com

24 apr. 2025, 16:05 UTC

Top știri
Câștiguri

Merck Cuts 2025 Outlook on Tariffs, Charges -- Update

24 apr. 2025, 14:36 UTC

Market Talk
Câștiguri

Merck's Challenges with Gardasil in China Continue -- Market Talk

24 apr. 2025, 14:10 UTC

Market Talk
Câștiguri

Merck's Mostly Steady Guidance Sees Current Tariffs Being Absorbed -- Market Talk

24 apr. 2025, 11:35 UTC

Câștiguri

Merck Lowers Earnings Guidance and Says Tariffs Will Hit Margins -- Barrons.com

24 apr. 2025, 10:58 UTC

Top știri
Câștiguri

Merck 1Q Net Up, But 2025 Adj EPS View Cut on Tariffs, Charges

24 apr. 2025, 10:55 UTC

Câștiguri

Merck Stock Rises After Earnings Even as Keytruda Sales Miss Estimates. Here's Why. -- Barrons.com

24 apr. 2025, 10:31 UTC

Câștiguri

Merck: 2025 Outlook Absorbs Estimated $200 Million Additional Costs for Tariffs Implemented to Date >MRK

24 apr. 2025, 10:30 UTC

Câștiguri

Merck 1Q Keytruda Sales $7.21B >MRK

24 apr. 2025, 10:30 UTC

Câștiguri

Merck 1Q Pharmaceutical Sales $13.64B >MRK

24 apr. 2025, 10:30 UTC

Câștiguri

Merck 1Q Keytruda Sales Up 4% >MRK

24 apr. 2025, 10:30 UTC

Câștiguri

Merck 1Q Januvia/Janumet Sales Up 19% >MRK

24 apr. 2025, 10:30 UTC

Câștiguri

Merck 1Q Pharmaceutical Sales Down 3% >MRK

24 apr. 2025, 10:30 UTC

Câștiguri

Merck 1Q Gardasil/Gardasil 9 Sales $1.33B >MRK

24 apr. 2025, 10:30 UTC

Câștiguri

Merck 1Q Januvia/Janumet Sales $796M >MRK

24 apr. 2025, 09:13 UTC

Acțiuni populare

Stocks to Watch Thursday: IBM, Tesla, Chipotle -- WSJ

24 mar. 2025, 05:00 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Chipotle and 4 More Buyback Stocks for a Down Market -- Barrons.com

5 mar. 2025, 19:42 UTC

Top știri

New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- Update

5 mar. 2025, 10:30 UTC

Top știri

New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- WSJ

5 feb. 2025, 12:00 UTC

Top știri

Merck Is Suffering From a Classic Pharma Problem -- Heard on the Street -- WSJ

4 feb. 2025, 14:48 UTC

Câștiguri

Merck Stock Plummets 10% As Gardasil Dynamics, 2025 Guidance Weigh On Shares -- IBD

4 feb. 2025, 11:51 UTC

Câștiguri

Merck's Soft Guidance Offsets Better-Than-Expected Fourth-Quarter Earnings -- MarketWatch

4 feb. 2025, 11:50 UTC

Câștiguri

Merck Stock Tumbles on Weak Guidance and Gardasil Sales Slump -- Barrons.com

4 feb. 2025, 11:31 UTC

Câștiguri

Merck 4Q Gardasil/Gardasil 9 Sales Down 17% >MRK

4 feb. 2025, 11:31 UTC

Câștiguri

Merck 4Q Gardasil/Gardasil 9 Sales $1.55B >MRK

4 feb. 2025, 11:31 UTC

Câștiguri

Merck 4Q Januvia/Janumet Sales Down 38% >MRK

Comparație

Modificare preț

Merck & Co Inc. Așteptări

Obiectiv de preț

By TipRanks

35.27% sus

Prognoză pe 12 luni

Medie 108 USD  35.27%

Maxim 138 USD

Minim 85 USD

În baza a 18 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruMerck & Co Inc. - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

18 ratings

11

Cumpărare

7

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

77.85 / 80.02Suport & Rezistență

Termen scurt

Bullish Evidence

Termen mediu

Strong Bearish Evidence

Termen lung

Bearish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.